New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
11:20 EDTSGENSeattle Genetics likely to gain approval in post-transplant HL, says Piper
Subscribe for More Information
09:01 EDTSGENSeattle Genetics says FDA accepts sBLA for Adcetris
Subscribe for More Information
April 10, 2015
07:21 EDTSGENExpert upbeat on Seattle Genetics Adcetris, says RBC Capital
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use